-5%
Arnivas Tablet | (Sacubitril + Valsartan Combination) | (97 mg+103 mg) Therapeutic Class: Neprilysin Inhibitor + Angiotensin Receptor Blocker (ARNI)
Arnivas is primarily used for the management of chronic heart failure. It is specifically indicated to:
- Reduce the risk of cardiovascular death and heart failure-related hospitalizations in adult patients with chronic heart failure and reduced ejection fraction (NYHA Class II–IV).
- Treat symptomatic heart failure in pediatric patients aged ≥1 year with systemic left ventricular systolic dysfunction.
This medication is typically used in combination with standard heart failure treatments and replaces ACE inhibitors (ACEi) or other ARBs in most treatment protocols.
